On May 12th a massive fire broke out at Marywilska 44, one of the Warsaw's largest shopping centers. This unexpected incident caused power outages in the surrounding area including the ICM data center where OpenAIRE services run. Efforts are underway to restore the power and to get services back online. Some functionalities will not work properly until then.
We apologize for any inconvenience this may have caused.
Powered by OpenAIRE graph
Found an issue? Give us feedback


Research and Development National Institute for Metals and Radioactive Resources
Country: Romania
186 Projects, page 1 of 38
  • Funder: European Commission Project Code: 847673
    Overall Budget: 100,000 EURFunder Contribution: 100,000 EUR

    This Coordination Action aims to prepare a EuroNanoForum 2019 (ENF2019) conference focused on "Nanotechnology and advanced materials progress under Horizon2020 and beyond", where an overview on cutting edge research in nanotechnology and advanced materials areas will be provided, featuring the opportunity to present the successful industrial implementations. The general objective of the ENF2019 is to attract a critical mass of researchers with relevant results and to facilitate their discussions with various stakeholders acting in nanotechnologies and advanced materials areas in NMBP. Also, EU and national policy makers will be invited and engaged in debates on future challenges and research priorities, especially in the perspectives of post-Horizon2020 scenarios. For that reason, the motto of the ENF2019 will be “Almost there - what’s next?. ENF2019 would be a forum of research and innovation developed under Horizon 2020 open to all entities producing excellent science, industrial leadership and tackling societal challenges. The goal is to review the achievements during Horizon2020 in world-class science production, innovation and as well as successful links to the public and private sectors working together in delivering innovation in all Horizon2020 priority areas. The event is planned to start with 2-day conference where distinguished speakers will be invited to initiate timely discussions and exchange ideas on scientific issues encountered in nanotechnology and advanced materials progress, as well as key policy, industrial and societal issues. A third day will be dedicated to networking between scientists, industrialists and policy makers to initiate future cooperation in research and innovation, to discuss strategic research priorities and to build partnerships for future funding calls, during the workshops and brokerage events. Industrial and research exhibition and posters are planned to complement the event package.

  • Funder: European Commission Project Code: 316194
    Powered by Usage counts
  • Funder: European Commission Project Code: 101078843
    Overall Budget: 2,446,250 EURFunder Contribution: 2,446,250 EUR

    Resistive switching refers to the controlled change in resistance of an electronic material, e.g. metal oxide, via the creation and modulation of nanoscale filaments. Although its physics is not yet fully understood, resistive switching devices (called memristors) are promising as efficient artificial synapses in neuro-inspired computing systems. However practical challenges exist. Current devices excel in only a few of the performance metrics necessary for circuit and system integration. Moreover, they exhibit non-idealities causing neuromorphic systems using these devices to have low performance. The project will address this key issue by pursuing device-system co-optimization across four objectives, aiming to engineer a single “hero” resistive switching technology with all the desired metrics. Aim 1 will develop resistive switching devices based on a new class of materials with broad compositional space, called high entropy oxides. Promising compositions will be fabricated in a high throughput fashion. In Aim 2, a proposed characterization method via a state-of-the-art mid-infrared laser will help understand in-operando the filamentary switching at nanoscale and uncover the physical mechanisms behind its non-idealities. The fabrication and characterization will iteratively target a broad range of performance metrics. Some metrics can only be quantified across a population of devices, so Aim 3 will integrate the optimized devices on transistor circuitry for benchmarking at scale. Aim 4 targets the applicability of these devices to next generation neuromorphic systems for machine learning training. Preliminary work on a multi-layer neural network validated this concept and indicated the need for co-optimization, as proposed. RobustNanoNet will address the interdisciplinary challenges towards a reliable resistive switching technology to support robust neuromorphic systems for energy efficient computing.

  • Funder: European Commission Project Code: 202897
  • Funder: European Commission Project Code: 101063613
    Funder Contribution: 133,736 EUR

    Multiple myeloma (MM) is an aggressive type of cancer of plasma cells where fast diagnosis and treatment monitoring is vital, especially given the overall low survival rate. Proteasome, a multi-catalytic complex essential in damaged protein degradation, has been recently established as a biomarker for MM, in which elevated levels have been observed in blood plasma of unhealthy individuals, as well as its impaired activity has been target for treatment alongside regular chemotherapy. PADMME addresses increasing contributions on proteasome electrochemical recognition and aims to develop novel interdisciplinary technologies translatable into POCT systems for MM care. For this, we propose the development of sensitive and selective dual-channel platforms comprising conductive polymeric fiber biosensors integrated on paper-based microfluidic supports to simultaneously detect quantity and specific activity of proteasome in blood plasma. Paper supports ensure disposability and ease of commercialization, whilst incorporation of microfluidic paths allows low sample volume requirements and in situ pre-treatment steps. Conductive polymeric fiber scaffolds provide increased signal resolution for the construction of biosensors, necessary for the recognition of low concentrations of the biomarker. Then, investigating proteasome at the dual-channel platform in drug-treated and untreated MM cell lines will demonstrate how changes in quantity and specific activity are specifically linked to the disease dynamics. The last step will comprise validation of the technology for analysis in blood plasma, technology able to improve overall monitoring of MM disease progression and therapeutic efficiency, crucial to overcome delays in treatment due to drug resistance complications. Training through research will allow me to refine my expertise, creativity and innovative potential on smart biosensor technologies translated into point-of-care testing devices for cancer care and drug assessment.


Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.